CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Cytos Biotechnology AG63 enrolled

Overview

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Allergic Bronchial Asthma

Interventions

CYT003-QbG10DRUG

subcutaneous injection

PlaceboDRUG

subcutaneous injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids * Further criteria as defined in the study protocol Exclusion Criteria: * Use of oral corticosteroids within past 3 months * Hospitalization for asthma exacerbation within past 6 months * Uncontrolled asthma * Contraindication to any study test or procedure * Further criteria as defined in the study protocol

Locations (1)

Cytos Investigator Sites

Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany

Outcomes

Primary Outcomes

Markers for inflammation and asthma

Time frame: 1-3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.